Literature DB >> 16044169

Memokath stents for the treatment of detrusor sphincter dyssynergia (DSD) in men with spinal cord injury: the Princess Royal Spinal Injuries Unit 10-year experience.

S S Mehta1, P R Tophill.   

Abstract

STUDY
DESIGN: Medical records review.
OBJECTIVE: To assess the effectiveness of the Memokath (Engineers and Doctors A/S, Denmark) thermosensitive stent as a 'nondestructive' means of reducing bladder outlet resistance by treating detrusor sphincter dyssynergia (DSD) of neurogenic bladder dysfunction associated with spinal cord injury.
SETTING: Spinal Injuries Unit, Sheffield, England.
METHODS: A medical records review was performed to examine our experience of Memokaths over the last 10 years. During this time, 29 patients with spinal cord injury (17 tetraplegic and 12 paraplegic) underwent stenting of the external urethral sphincter either for prevention of dysreflexic symptoms, high residual urine volumes and subsequent urinary tract infection (UTI) or for protection of the upper tracts.
RESULTS: A total of 33 stents were inserted into 29 men (25-77 years) with suprasacral spinal cord injury. Initial results showed that the Memokath was effective in almost all for relief of dysreflexic symptoms and elimination of DSD on pressure flow urodynamics. However, to date, 30 of the 33 stents have been removed. The overall mean working life of the Memokath was 21 months. Four stents were removed electively and 23 for complications, which included stent migration (seven) and blockage (14). Single-ended stents were more prone to migration, which was rare after 1 year (1-13 months, median 3 months, mean 5.5 months). Stent blockage by encrustation or prostatic ingrowth did not occur before 12 months (12-45 months, median 30, mean 27.9 months).
CONCLUSIONS: In selected patients, temporary, thermo-expandable (Memokath) stents are effective in the treatment of DSD. The 'working life' of a Memokath stent is 21 months; however, complications do occur which may necessitate removal. Our overall experience with Memokath stents was disappointing. In future, Memokath stents will only be inserted after careful consideration in patients with prior 'failed' transurethral sphincterotomy or with caution in patients suitable for reconstructive surgery.

Entities:  

Mesh:

Year:  2006        PMID: 16044169     DOI: 10.1038/sj.sc.3101800

Source DB:  PubMed          Journal:  Spinal Cord        ISSN: 1362-4393            Impact factor:   2.772


  7 in total

1.  Managing the urinary tract in spinal cord injury.

Authors:  Simon C W Harrison
Journal:  Indian J Urol       Date:  2010-04

Review 2.  Neurogenic bladder in spinal cord injury patients.

Authors:  Waleed Al Taweel; Raouf Seyam
Journal:  Res Rep Urol       Date:  2015-06-10

Review 3.  Detrusor sphincter dyssynergia: a review of physiology, diagnosis, and treatment strategies.

Authors:  John T Stoffel
Journal:  Transl Androl Urol       Date:  2016-02

4.  Urethral Stenting for Obstructive Uropathy Utilizing Digital Radiography for Guidance: Feasibility and Clinical Outcome in 26 Dogs.

Authors:  A Radhakrishnan
Journal:  J Vet Intern Med       Date:  2017-01-29       Impact factor: 3.333

5.  The accumulation of particles in ureteric stents is mediated by flow dynamics: Full-scale computational and experimental modeling of the occluded and unoccluded ureter.

Authors:  Ali Mosayyebi; Aravinthan Vijayakumar; Maryam Mosayebi; Dirk Lange; Bhaskar K Somani; Costantino Manes; Dario Carugo
Journal:  APL Bioeng       Date:  2022-05-05

6.  Thermo-expandable metallic urethral stents for managing recurrent bulbar urethral strictures: To use or not?

Authors:  Mohamed M Abdallah; Mohamed Selim; Tarek Abdelbakey
Journal:  Arab J Urol       Date:  2013-01-23

7.  Early experience with a thermo-expandable stent (memokath) for the management of recurrent urethral stricture.

Authors:  Hyun Su Jung; Joon Woo Kim; Jun Nyung Lee; Hyun Tae Kim; Eun Sang Yoo; Bum Soo Kim
Journal:  Korean J Urol       Date:  2013-12-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.